Substance and claimed effects

Sudden sensorineural hearing loss (SSNHL) is a rapid-onset hearing loss in one ear caused by injury to the cochlea, the auditory nerve, or central auditory pathways. The AAO-HNS clinical practice guideline defines it audiometrically as a sensorineural drop of at least 30 dB across three contiguous frequencies, developing within 72 hours, when compared to the unaffected ear or a prior audiogram Chandrasekhar et al. 2019. In over 90% of cases no cause is ever found (idiopathic SSNHL, or ISSNHL); the remainder are explained by vestibular schwannoma, vascular events, autoimmune inner ear disease, infections (HSV, VZV, CMV, syphilis, Lyme), Meniere's, trauma, demyelination, or ototoxicity. The substance covered here is the condition itself: its recognition, the emergency-window logic that follows from its short steroid efficacy curve, and the trajectory of hearing afterward. Meaningful downstream consequences include residual hearing in the affected ear, chronic tinnitus, hyperacusis, the mood and social-isolation burden of unilateral deafness, and the cognitive-load tax of single-sided hearing in noise.

Evidence by addressing question

Mechanism

Science. The 2019 guideline catalogues the leading mechanistic hypotheses for idiopathic SSNHL: viral cochleitis (latent neurotropic viruses reactivating in the spiral ganglion), microvascular occlusion of the labyrinthine artery (an end-artery with no collateral supply), intracochlear membrane rupture, and autoimmune attack on inner-ear antigens Chandrasekhar et al. 2019. None has been confirmed as the dominant cause; the guideline panel explicitly chose the empirical strategy — treat broadly with corticosteroids because the mechanism is anti-inflammatory enough to cover several plausible pathologies — over waiting for a mechanism-first approach.

Mechanism. The cochlea is uniquely fragile: hair cells do not regenerate in humans, and the stria vascularis depends on a single end-artery. Any inflammatory, ischaemic, or autoimmune insult that outlasts a narrow window kills hair cells permanently. This explains the time-pressure clinically observed even before the mechanism is named: every day of unresolved insult risks structural loss that no later treatment can reverse.

Evidence

Science. Annual incidence in the United States is approximately 27 per 100,000 overall, rising to 77 per 100,000 in adults aged 65+, based on claims-database analysis of more than 60 million enrollees Alexander & Harris 2013. Earlier estimates of 5–20 per 100,000 likely underestimated true incidence because of under-presentation and miscoding as conductive loss NIDCD. The natural history baseline comes from Mattox and Simmons, who reported that roughly 65% of untreated patients recovered to functional hearing levels, most within 14 days Mattox & Simmons 1977. This is the rate any therapy must beat to claim efficacy, and is also why under-treatment so often gets retrospectively excused ("they got better anyway").

The pivotal corticosteroid trial is Rauch et al., a multicentre randomised non-inferiority trial of 250 patients with unilateral SSNHL of ≥50 dB presenting within 14 days. Intratympanic methylprednisolone was non-inferior to oral prednisone at two months; the 95.21% upper confidence bound on the oral-prednisone advantage was 6.6 dB Rauch et al. 2011. The trial established the two-week presentation window as the clinically actionable one and is the basis for both 2012 and 2019 guideline recommendations Stachler et al. 2012 Chandrasekhar et al. 2019.

Recovery is strongly stratified by severity and audiogram shape. Profound losses (>90 dB) almost never recover regardless of treatment; flat and downsloping curves recover poorly (19–56%); low-frequency and upsloping curves recover well (63–88%). Vertigo at onset and age >60 predict worse outcomes.

Practice / clinical consensus. The AAO-HNS guideline grades a strong recommendation that clinicians distinguish sensorineural from conductive loss at presentation, and offer corticosteroids within two weeks of onset as the initial therapy; intratympanic corticosteroids are recommended as salvage within 2–6 weeks Chandrasekhar et al. 2019. Routine head CT, antivirals, thrombolytics, and vasodilators are recommended against. MRI or auditory brainstem response is recommended to rule out retrocochlear pathology (most commonly vestibular schwannoma).

Protocol

Science / Practice. The standard initial regimen drawn from Rauch and codified in the guideline is oral prednisone 1 mg/kg/day (max 60 mg) for 10–14 days, then tapered Rauch et al. 2011 Chandrasekhar et al. 2019. Intratympanic dexamethasone or methylprednisolone, delivered through the eardrum, is offered as initial therapy when oral steroids are contraindicated (poorly controlled diabetes, peptic ulcer disease, psychiatric instability), and as salvage when oral therapy is incomplete at 2–6 weeks. Hyperbaric oxygen therapy is a conditional option ("may be offered") within 2 weeks of onset combined with steroids, or as salvage within one month, with a small absolute hearing-gain benefit reported in meta-analysis but modest study quality Bennett et al. 2012. Audiology referral is recommended for hearing aids, CROS devices, or cochlear implant evaluation when residual loss is unrecoverable.

Contraindications

Practice. The contraindications belong to the treatment, not the diagnosis. Oral high-dose corticosteroids carry risks: hyperglycaemia in diabetes, gastric ulcer in NSAID users, psychiatric destabilisation, avascular necrosis with prolonged courses, immunosuppression. Intratympanic steroids carry small procedural risks (eardrum perforation, infection, dizziness). The guideline panel weighed these against the irreversibility of untreated hearing loss and concluded the benefit-risk balance favours treatment for nearly every otherwise-healthy adult, with intratympanic as the route when systemic steroids are unsafe Chandrasekhar et al. 2019.

Misconceptions

Practice / Community. The dominant clinical-practice failure is misattribution at first contact. Patients themselves, urgent-care clinicians, and primary-care physicians frequently attribute sudden one-sided hearing loss to earwax, a sinus infection, allergies, eustachian tube dysfunction, or a recent cold. The case-by-case error is small (most ear infections do resolve); the systematic error is large, because SSNHL has a steep treatment-window decay and an irrigation, decongestant, or wait-and-see plan burns days off the window. The guideline writes an explicit recommendation against attributing presumptive SSNHL to cerumen or otitis with media before tuning-fork testing Chandrasekhar et al. 2019.

A second misconception is that hearing "always comes back". Mattox and Simmons' 65% spontaneous recovery rate is genuine but conditional — it falls sharply with greater severity, downsloping audiogram, age, and vertigo, and complete spontaneous recovery is rare in severe-to-profound losses Mattox & Simmons 1977.

Stakes

Science. Time-to-treatment is the modifiable variable that most strongly predicts recovery. Across observational series, recovery odds are high in the first week and drop steeply afterward; presentations beyond two weeks lose access to the trial-supported steroid window, and salvage intratympanic steroids have a narrower benefit and a 2–6 week ceiling Chandrasekhar et al. 2019. Permanent unilateral hearing loss compounds: bilateral spatial hearing is lost, speech-in-noise comprehension drops disproportionately, tinnitus often persists in the dead ear, and longitudinal data on chronic hearing loss link it to higher rates of depression, social withdrawal, and accelerated cognitive decline.

Payoff

Science. Patients presenting within the first week and treated with oral prednisone have substantially higher complete-recovery rates than those presenting after 2–4 weeks; the Rauch trial's 14-day enrolment window directly reflects this clinical observation Rauch et al. 2011. The realistic payoff of fast action is not guaranteed full recovery — that depends on initial severity and audiogram shape — but it is the highest achievable probability of full recovery and the cleanest avoidance of permanent unilateral deafness.

Audience

Science. Incidence rises with age, peaking after 65 Alexander & Harris 2013, but cases occur from childhood onward and the largest proportion of new cases is in adults 40–60. Male-to-female ratio is approximately 1:1. Audience scoping for this entry is "all adults" with informational priority for ages 40+ where incidence climbs and pre-existing age-related hearing loss can mask the unilateral drop.

Practicalities

Practice. Emergency department, urgent care, or same-day ENT (otolaryngology) are the appropriate first stops. Audiometry confirms the diagnosis; a Weber tuning-fork test lateralising to the unaffected ear is the bedside screen when audiometry is not immediately available. MRI of the internal auditory canals follows to rule out retrocochlear pathology. Oral steroid courses are inexpensive and widely covered. Intratympanic injection is an in-office otolaryngology procedure typically covered by health insurance. The high-cost downstream interventions are reserved for unrecovered cases: CROS hearing aids ($2–6k), bone-anchored hearing aids ($5–10k), and cochlear implants ($40–100k including surgery and follow-up).

Out of scope

Acoustic trauma, noise-induced hearing loss, age-related sensorineural hearing loss, ototoxic medication injury, conductive losses (otitis, otosclerosis, perforated eardrum), and chronic Meniere's disease all share final-common-pathway features with SSNHL but have separate diagnostic and management pathways and warrant their own entries.

The credibility range

Optimist case. The 2019 AAO-HNS guideline is the strongest evidence-based consensus in otology for a time-sensitive condition. The pivotal Rauch trial is a well-powered multicentre randomised non-inferiority study with an active comparator, not a placebo-controlled trial — but the field considers placebo-controlling a treatable emergency unethical, and the active-comparator design plus the Mattox-Simmons natural-history baseline together give a defensible inferential foundation. Steroid therapy is cheap, widely available, and the time-window evidence is consistent across multiple observational series. Acting fast genuinely changes outcomes.

Skeptic case. The single placebo-controlled steroid trial that exists (Wilson 1980) is small and old, and meta-analyses have not consistently shown steroid superiority over no treatment. About two-thirds of patients recover spontaneously, which means many observed "steroid wins" are misattributions. The 14-day window is a trial enrolment cut-off, not a biologically validated cliff edge; some observational data show benefit at 4–6 weeks too. Hyperbaric oxygen is recommended on the strength of a small effect size from underpowered trials. The guideline panel itself acknowledges the evidence is "C"-grade for much of the protocol.

Author's call. The Skeptic case is technically correct on the trials, but the asymmetric loss function dominates: untreated SSNHL has a real and irreversible failure mode (permanent unilateral deafness), oral corticosteroids are low-cost and low-risk for most otherwise-healthy adults, and the marginal recovery improvement, even if uncertain, comes at trivial cost. The medical-emergency framing is appropriate and the "treat fast" protocol is the right default. Where uncertainty justifies softer language: hyperbaric oxygen sits at the edge of recommended; routine antiviral use is correctly recommended against; the 14-day boundary is a presumption rather than a guarantee — later presentations should still be evaluated and treated, just with lower expected return.

Stakeholder and incentive map

Otolaryngology guideline bodies (AAO-HNS) push the medical-emergency framing because they see the long tail of permanent unilateral deafness cases that arrived too late. Emergency medicine has historically under-recognised the condition because tuning-fork testing is variably taught and the chief complaint "my ear feels blocked" presents non-emergently. Hyperbaric medicine groups push HBOT, with a commercial incentive (HBOT centres charge per session). Hearing-aid and cochlear-implant manufacturers benefit from unrecovered cases but are not the primary advocates for the emergency framing. Patient-advocacy groups (Hearing Loss Association of America) reinforce the emergency framing in lay communication.

Population variability

Best recovery prognoses: younger patients, low-frequency or upsloping audiogram, mild-to-moderate initial loss, no vertigo at onset, no diabetes or cardiovascular comorbidity, presentation within seven days. Worst prognoses: age >60, profound initial loss (>90 dB), flat or downsloping audiogram, accompanying vertigo, hypertension or diabetes, late presentation. Children and elderly patients with profound bilateral loss require modified workup — the bilateral or recurrent presentation specifically demands autoimmune and CNS workup beyond the standard SSNHL pathway Chandrasekhar et al. 2019.

Knowledge gaps

The dominant unknown is mechanism. Without a confirmed cause for the majority of cases, treatment remains empirical and unable to be optimised by pathology. A modern placebo-controlled corticosteroid RCT will not be done because the condition is now considered an emergency and equipoise is gone — the field is locked into the current empirical protocol whether or not steroids exceed the natural-history baseline. The role of antiviral therapy in HSV/VZV-proven cases remains under-studied. The COVID-era association between SARS-CoV-2 and SSNHL incidence is contested; case-control evidence has not consistently shown a population-level effect. Cochlear hair-cell regeneration therapies (atoh1, Notch-pathway, gene therapy) are in early trials and could change the recovery landscape but are not yet clinically available.

Brief vs coverage. The brief named three things: emergency framing, the steroid window, and recovery effects. All three are covered end to end (mechanism + evidence + misconceptions for the emergency framing; protocol + contraindications for the steroid window; stakes + payoff + failure-modes for recovery). Nothing dropped.

Scoring difficulties. The benefit dimensions on a respond condition are inherently indirect — the "benefit" is the downstream loss avoided, not a felt effect of the intervention itself. The pitches were rewritten several times to surface that asymmetry without sounding fear-mongering. energy at 1 and focus at 2 are the smallest defensible non-zero scores; the dossier earns them through the speech-in-noise effort literature, not through a direct cognitive-boost story. longevity at 2 borrows from the hearing-loss / cognitive-decline / dementia association literature; the chain is real but indirect, which is why it sits at 2 rather than 3.

Controversy at 2. The steroid efficacy debate against the natural-history baseline is genuine but mostly a clinician-internal debate at this point; the public-facing field treats the protocol as settled. Scoring 2 reflects that — real disagreement, low temperature.

Excluded on purpose. Long-form post-recovery management (cochlear implants, CROS, bone-anchored hearing aids, chronic tinnitus management) belongs in its own entries — the action-payoff arc here is the emergency response, not the long-tail aftercare. Hearing-loss-and-dementia gets a single referenced sentence in stakes but not a whole section; it warrants its own entry under hearing or mental.

Separate-entry candidates.

• Vestibular schwannoma (acoustic neuroma) — surfaces here as "rule it out with MRI" but is a substantial topic with its own decision tree.
• Chronic tinnitus management — the "there is no off switch" line earns a dedicated entry.
• Hearing-loss-and-cognitive-decline — longitudinal evidence justifies its own entry on the prevention side.
• Cochlear implants and CROS devices for single-sided deafness — the salvage-path entry.
• Hyperbaric oxygen for SSNHL — mentioned in protocol but the controversy and cost-effectiveness merit a focused entry.

Future links. Once written: tuning-fork bedside testing (the 30-second test referenced in misconceptions), audiometry as a screening tool, the hearing-loss / dementia entry.

Tone calibration. The article repeatedly resists the temptation to escalate language — "medical emergency" appears once in the dek and once in the protocol section, deliberately, because the symptom genuinely does present as "probably wax" and over-dramatising loses the audience that needs to hear it. The asymmetric-loss argument carries the urgency instead.